Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

1. Dapagliflozin in Patients with Chronic Kidney Disease. (Abstract)

Dapagliflozin in Patients with Chronic Kidney Disease. Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.We randomly assigned 4304 participants with an estimated glomerular filtration rate (GFR) of 25 to 75 ml per minute per 1.73 m2 of body-surface area and a urinary albumin-to-creatinine ratio (with albumin measured in milligrams (...) and creatinine measured in grams) of 200 to 5000 to receive dapagliflozin (10 mg once daily) or placebo. The primary outcome was a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes.The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome event occurred in 197 of 2152 participants (9.2%) in the dapagliflozin group and 312 of 2152

2020 NEJM

2. Calcium channel blockers for people with chronic kidney disease requiring dialysis. Full Text available with Trip Pro

Calcium channel blockers for people with chronic kidney disease requiring dialysis. Calcium channel blockers (CCBs) are used to manage hypertension which is highly prevalent among people with chronic kidney disease (CKD). The treatment for hypertension is particularly challenging in people undergoing dialysis.To assess the benefits and harms of calcium channel blockers in patients with chronic kidney disease requiring dialysis.We searched the Cochrane Kidney and Transplant Register of Studies (...) across studies. Well-designed RCTs, conducted in both adults and children with CKD requiring both haemodialysis and peritoneal dialysis, evaluating both dihydropyridine and non-dihydropyridine CCBs against other antihypertensives are required. Future research should be focused on outcomes relevant to patients (including death and cardiovascular disease), blood pressure changes, risk of side effects and healthcare costs to assist decision-making in clinical practice.Copyright © 2020 The Cochrane

2020 Cochrane

3. Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis : An Individual Participant-Based Meta-analysis. (Abstract)

Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis : An Individual Participant-Based Meta-analysis. Although measuring albuminuria is the preferred method for defining and staging chronic kidney disease (CKD), total urine protein or dipstick protein is often measured instead.To develop equations for converting urine protein-creatinine ratio (PCR) and dipstick protein to urine albumin (...) dipstick protein may help in CKD screening, staging, and prognosis.National Institute of Diabetes and Digestive and Kidney Diseases and National Kidney Foundation.

2020 Annals of Internal Medicine

4. Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease

critical illness, chronic obstructive pulmonary disease and chronic heart failure. Management for muscle weakness or dysfunction caused by chronic respiratory conditions, chronic heart failure or chronic kidney disease includes lifestyle Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (IPG677) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights (...) Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease Interventional procedures guidance Published: 5 August 2020 www.nice.org.uk/guidance/ipg677 Your responsibility Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence

2020 National Institute for Health and Clinical Excellence - Interventional Procedures

5. Intravenous thrombolysis in patients with chronic kidney disease: A systematic review and meta-analysis

Intravenous thrombolysis in patients with chronic kidney disease: A systematic review and meta-analysis Intravenous thrombolysis in patients with chronic kidney disease: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Neurology Actions . 2020 Jul 14;95(2):e121-e130. doi: 10.1212/WNL.0000000000009756. Epub 2020 Jun 17. Intravenous thrombolysis in patients with chronic kidney disease: A systematic review and meta-analysis , , , , , , , , , , Affiliations

2020 EvidenceUpdates

6. Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronic kidney disease: the BiCARB RCT Full Text available with Trip Pro

Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronic kidney disease: the BiCARB RCT Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronic kidney disease: the BiCARB RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search (...) of Dundee, Dundee, UK 12 Ageing Clinical and Experimental Research, University of Aberdeen, Aberdeen, UK 13 Department of Medicine for the Elderly, NHS Tayside, Dundee, UK 14 John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK 15 Health Services Research Unit, University of Aberdeen, Aberdeen, UK * Corresponding author Email: {{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}} Citation

2020 NIHR HTA programme

7. Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial

Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation JAMA Surg Actions . 2020 Jun 3;e200420. doi: 10.1001/jamasurg.2020.0420. Online ahead of print. Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial , , , , , , , , , , , , , , , , , , Affiliations Expand

2020 EvidenceUpdates

8. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Randomized Controlled Trial Lancet Diabetes Endocrinol Actions . 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

2020 EvidenceUpdates

9. Effects of combined aerobic and resistance exercise on renal function in adult patients with chronic kidney disease: a systematic review and meta-analysis

Effects of combined aerobic and resistance exercise on renal function in adult patients with chronic kidney disease: a systematic review and meta-analysis Effects of combined aerobic and resistance exercise on renal function in adult patients with chronic kidney disease: a systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions . 2020 Jul;34(7):851-865. doi: 10.1177/0269215520924459. Epub 2020 Jun 8. Effects of combined aerobic and resistance exercise on renal function in adult patients with chronic kidney disease: a systematic review and meta-analysis , , , , , Affiliations Expand Affiliations 1 School of Nursing, Fujian Medical University

2020 EvidenceUpdates

10. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. (Abstract)

Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Hyperkalaemia is a common electrolyte abnormality caused by reduced renal potassium excretion in patients with chronic kidney diseases (CKD). Potassium binders, such as sodium polystyrene sulfonate and calcium polystyrene sulfonate, are widely used but may lead to constipation and other adverse gastrointestinal (GI) symptoms, reducing their tolerability. Patiromer and sodium zirconium cyclosilicate are newer ion (...) , and policy-makers.To assess the benefits and harms of potassium binders for treating chronic hyperkalaemia among adults and children with CKD.We searched the Cochrane Kidney and Transplant Register of Studies up to 10 March 2020 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal

2020 Cochrane

11. Effects of Allopurinol on the Progression of Chronic Kidney Disease. (Abstract)

Effects of Allopurinol on the Progression of Chronic Kidney Disease. Elevated serum urate levels are associated with progression of chronic kidney disease. Whether urate-lowering treatment with allopurinol can attenuate the decline of the estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease who are at risk for progression is not known.In this randomized, controlled trial, we randomly assigned adults with stage 3 or 4 chronic kidney disease and no history of gout (...) who had a urinary albumin:creatinine ratio of 265 or higher (with albumin measured in milligrams and creatinine in grams) or an eGFR decrease of at least 3.0 ml per minute per 1.73 m2 of body-surface area in the preceding year to receive allopurinol (100 to 300 mg daily) or placebo. The primary outcome was the change in eGFR from randomization to week 104, calculated with the Chronic Kidney Disease Epidemiology Collaboration creatinine equation.Enrollment was stopped because of slow recruitment

2020 NEJM

12. The Management of Chronic Kidney Disease

The Management of Chronic Kidney Disease Management of Chronic Kidney Disease (CKD) (2019) - VA/DoD Clinical Practice Guidelines Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu (...) links. Get help from Veterans Crisis Line Locator Contact Search Contact Us Locator Get help from Veterans Crisis Line Search Enter your search text Button to start search More VA More VA Inside VA Budget and Performance Inside the Media Room National Observances Special Events » » » » » Management of Chronic Kidney Disease (CKD) (2019) VA/DoD Clinical Practice Guidelines Menu Menu Quick Links Enter ZIP code here Enter ZIP code here Management of Chronic Kidney Disease (CKD) (2019) Newly Updated

2020 VA/DoD Clinical Practice Guidelines

13. Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. (Abstract)

Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Malnutrition is common in patients with chronic kidney disease (CKD) on dialysis. Oral protein-based nutritional supplements are often provided to patients whose oral intake is otherwise insufficient to meet their energy and protein needs. Evidence for the effectiveness of oral protein-based nutritional supplements in this population is limited.The aims of this review were (...) to determine the benefits and harms of using oral protein-based nutritional supplements to improve the nutritional state of patients with CKD requiring dialysis.We searched the Cochrane Kidney and Transplant Register of Studies up to 12 December 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP

2020 Cochrane

14. A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease

A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease A Randomized Trial of Distal Diuretics Versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Create file Cancel Actions Cite Share Permalink Copy Page navigation J Am Soc Nephrol Actions . 2020 Mar;31(3):650-662. doi: 10.1681/ASN.2019090905. Epub 2020 Jan 29. A Randomized Trial of Distal Diuretics Versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease , , , , , , , , , Affiliations Expand Affiliations 1 Divisions of Nephrology and Transplantation. 2 Dietetics, and. 3 Division of Pharmacology, Department of Pharmaceutical Sciences, University Utrecht, Utrecht

2020 EvidenceUpdates

15. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Full Text available with Trip Pro

Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Health system planning requires careful assessment of chronic kidney disease (CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-existent in many countries. We estimated the global, regional, and national burden of CKD, as well as the burden of cardiovascular disease and gout attributable to impaired kidney function (...) , for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. We use the term CKD to refer to the morbidity and mortality that can be directly attributed to all stages of CKD, and we use the term impaired kidney function to refer to the additional risk of CKD from cardiovascular disease and gout.The main data sources we used were published literature, vital registration systems, end-stage kidney disease registries, and household surveys. Estimates of CKD burden were produced using a Cause

2020 Lancet

16. Pharmacological interventions for heart failure in people with chronic kidney disease. (Abstract)

Pharmacological interventions for heart failure in people with chronic kidney disease. Approximately half of people with heart failure have chronic kidney disease (CKD). Pharmacological interventions for heart failure in people with CKD have the potential to reduce death (any cause) or hospitalisations for decompensated heart failure. However, these interventions are of uncertain benefit and may increase the risk of harm, such as hypotension and electrolyte abnormalities, in those with CKD.This (...) proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.We included randomised controlled trials of any pharmacological intervention for acute or chronic heart failure, among people of any age with chronic kidney disease of at least three months duration.Two authors independently screened the records to identify eligible studies and extracted data on the following dichotomous outcomes: death, hospitalisations, worsening heart failure, worsening kidney function

2020 Cochrane

17. Management of Chronic Kidney Disease

Disease Guideline, July 2019 Clinical Problem and Management Issues Chronic kidney disease (CKD) is an increasingly common clinical problem that raises a patient’s risk for developing several life-threatening medical conditions, including end- stage renal disease (ESRD) and cardiovascular disease (CVD). Appropriate treatment can delay or prevent these adverse outcomes. However, CKD is often not recognized by clinicians or patients and as a result is often not optimally treated. Prevalence (...) indicating presence of abnormal kidney structure or function for 3 or more months can establish the diagnosis of CKD (Table 1). Ruling out acute (or acute on chronic) kidney injury involves clinical 13 UMHS Chronic Kidney Disease Guideline, July 2019 judgment in the clinical context of either estimated GFR (eGFR) 20% in eGFR, or an increase in serum creatinine = 0.3. During the initial evaluation of CKD, common causes and predisposing conditions for acutely decreased eGFR, including pre-renal and post

2020 University of Michigan Health System

18. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease

in HF patients and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 . We conducted a systematic review evaluating the efficacy and safety of MRA in patients with HF and CKD. PubMed, Embase, and Cochrane Central databases were searched for relevant studies on patients with HF and reduced renal function (defined as eGFR <60 mL/min/1.73 m 2 ). Seven studies with 5,522 patients were included. We found 3 studies in patients with HFrEF, 1 study with HFpEF (...) Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily

2020 EvidenceUpdates

19. COVID-19 and Patients with Chronic Kidney Disease (CKD) and End-stage Renal Disease (ESRD)

, calcineurin inhibitors, and mTOR inhibitors for patients with COVID-19 who develop acute kidney injury requiring renal replacement therapy, see also see also for additional information Patients With Chronic Kidney Disease (CKD) General Consideration PubMed 32204907 Kidney international Kidney Int 20200307 patients with existing conditions can be more susceptible to COVID-19 and likely to experience more severe illness ( , , ) existing conditions include CKD, with any of the following decreased kidney (...) COVID-19 and Patients with Chronic Kidney Disease (CKD) and End-stage Renal Disease (ESRD) COVID-19 and Patients with Chronic Kidney Disease (CKD) and End-stage Renal Disease (ESRD) You need to enable JavaScript to run this app. Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow. Subscribe Already subscribed? Specialties 0 English COVID-19 and Patients with Chronic Kidney Disease (CKD) and End-stage Renal Disease (ESRD) Follow Share

2020 DynaMed Plus

20. COVID-19 rapid guideline: chronic kidney disease

Patients known or suspected to have COVID-19 8 3 Managing chronic kidney disease (CKD) 9 Modifying usual care 9 Medicines 9 Monitoring CKD 10 4 Specialist services 11 Referrals to renal services 11 Renal ultrasound 11 Hospital admission 12 5 Advanced chronic kidney disease 13 6 Healthcare workers 14 COVID-19 rapid guideline: chronic kidney disease (NG176) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 14Overview (...) . Be aware that there is no evidence from clinical or epidemiological studies that ACE inhibitors or angiotensin receptor blockers might worsen COVID-19. See: • the Renal Association UK position statement on COVID-19 and ACE inhibitor/ angiotensin receptor blocker use COVID-19 rapid guideline: chronic kidney disease (NG176) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 9 of 14• the Renal Association guidance

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines